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Huntington’s disease (HD) is an inherited neurodegenerative disorder typified by
involuntary body movements, and psychiatric and cognitive abnormalities. Many
HD patients also exhibit metabolic changes including progressive weight loss and
appetite dysfunction. Here we have investigated metabolic function in pre-manifest
and manifest HD subjects to establish an HD subject metabolic hormonal plasma
signature. Individuals at risk for HD who have had predictive genetic testing showing
the cytosine-adenine-guanine (CAG) expansion causative of HD, but who do not yet
present signs and symptoms sufficient for the diagnosis of manifest HD are said to
be “pre-manifest.” Pre-manifest and manifest HD patients, as well as both familial and
non-familial controls, were evaluated for multiple peripheral metabolism signals including
circulating levels of hormones, growth factors, lipids, and cytokines. Both pre-manifest
and manifest HD subjects exhibited significantly reduced levels of circulating growth
factors, including growth hormone and prolactin. HD-related changes in the levels of
metabolic hormones such as ghrelin, glucagon, and amylin were also observed. Total
cholesterol, HDL-C, and LDL-C were significantly decreased in HD subjects. C-reactive
protein was significantly elevated in pre-manifest HD subjects. The observation of
metabolic alterations, even in subjects considered to be in the pre-manifest stage of
HD, suggests that in addition, and prior, to overt neuronal damage, HD affects metabolic
hormone secretion and energy regulation, which may shed light on pathogenesis, and
provide opportunities for biomarker development.
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INTRODUCTION
Huntington’s disease (HD) is a neurodegenerative disorder
involving the extrapyramidal motor system and is characterized
by chorea, progressive dementia, and other psychiatric symptoms
(Walker, 2007; Ross and Tabrizi, 2011;Weir et al., 2011). The inci-
dence of HD is approximately 5–10 cases per 100,000 worldwide,
making it one of the most common inherited neurodegenera-
tive disorders. HD is caused by a dominant genetic mutation
in the huntingtin (HTT) gene that results in an expanded tri-
nucleotide repeat of cytosine-adenine-guanine (CAG). This CAG
repeat codes for an expanded polyglutamine repeat near the
N-terminus of the HTT protein, which undergoes a conforma-
tional change, and causes cellular damage (Walker, 2007). The
areas of the brain most affected by mutant HTT are the striatum,
followed by the cerebral cortex, and then other brain regions. The
onset of HD typically occurs around the age of 30–40, and as
the disease develops patients progressively lose independence and,
eventually, die.
Many HD patients suffer from weight loss and as a result it
is believed that metabolic dysfunction contributes to HD patho-
genesis (Martin et al., 2008; Van Der Burg et al., 2009; Cai et al.,
2012). Aziz et al. (2010a) reported that in HD patients, energy
expenditure in a fasted state is increased compared to healthy
control subjects, suggesting that a hypermetabolic state could
contribute to the observed increase in energy expenditure in HD
(Aziz et al., 2010a). Further reinforcing the presence of somatic
metabolic dysfunction in HD, abnormal insulin, and leptin secre-
tion rates have been shown to be positively correlated with higher
CAG repeat number (Aziz et al., 2010b), which may contribute
to the weight loss that is evident in many HD patients. The
R6/2 transgenic mouse, which express exon 1 of human HD gene
with around 150 CAG repeats (Mangiarini et al., 1996), is the
most widely used mouse model to study HD pathology. Blood
glucose levels in R6/2 HD mice are significantly higher than in
wild type controls. Reduced insulin production is also evident in
this model (Andreassen et al., 2002). In addition, the N171-82Q
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murine HD model expressing a 171 amino acid- N-terminal
human HTT cDNA insertion giving rise to an 82 CAG repeat
expansion, displays multiple aspects of diabetic-like pathophys-
iology (Martin et al., 2009, 2012). It has been demonstrated that
anti-diabetic therapeutics can ameliorate the metabolic dysfunc-
tion present in this model (Martin et al., 2012). Deletion of
huntingtin-associated protein 1 (HAP1), in pancreatic beta cells
has also been shown to result in impaired glucose tolerance by
reducing glucose-mediated insulin release in these mice (Kaushik
et al., 2011).
In the current study, we recruited both pre-manifest and man-
ifest HD subjects in order to conduct an investigation of the
metabolic profile in HD, through the measurement of brain and
metabolic hormone levels; lipid profiling and cytokine levels.
We recruited familial control groups, to primarily control for
lifestyle variables, and Baltimore Longitudinal Study of Aging
(BLSA) control groups to effectively control for age, gender com-
position and BMI influences. We found that growth hormone
(GH) and prolactin were significantly decreased in the manifest
HD subjects. In the fasted state, HD subjects presented similar
blood sugar, insulin, and adiponectin levels compared to all con-
trol groups, whereas plasma ghrelin, glucagon, and amylin levels
were significantly altered. Total cholesterol (CH) levels as well
as the high-density lipoprotein-cholesterol (HDL-C) and low-
density lipoprotein-cholesterol (LDL-C) levels in HD subjects
were decreased. Our findings indicate that HD patients possess
impaired energy homeostasis and abnormal hormone levels. This
state can be detected as distinctive metabolic plasma “signature,”
even in the early pre-manifest stage of HD. These findings sug-
gest that, in addition to neuronal damage, HD pathogenesis could
involve widespread metabolic dysfunction.
MATERIALS AND METHODS
RESEARCH SUBJECTS
Institutional Review Board approval was obtained from the
National Institute on Aging, and informed written consent was
obtained from all participants. Fifteen pre-manifest and eight
manifest HD subjects, as well as 16 control subjects from the
patient’s families were recruited for this study (Johns Hopkins
familial cohort). Due to the difficulty of matching for age, body
mass index (BMI), and gender in familial controls, we employed
additional control subjects from the BLSA. The BLSA subjects
are healthy people without diagnosed metabolic or neuronal dis-
eases. With the BLSA control subjects we were able to avoid
confounding factors such as body weight, age, and gender. Thus,
BLSA control groups adequately control for age, gender, and BMI,
while the Johns Hopkins familial control group control for the
socioeconomic status and prevalent stress levels in the HD subject
groups, as familial caregivers experience similar stressors/home
environment as the HD subjects. Hence the BLSA pre-manifest
control group matched pre-manifest subjects and the BLSA man-
ifest control group matched the manifest subjects. Characteristics
of all the subject groups are listed in Table 1. Blood samples
were collected separately during each subject’s visit to the hos-
pital. Blood samples of subjects from Johns Hopkins hospital
were taken in the morning after an over-night fast. Plasma sam-
ples were centrifuged at 3000 rpm at 4◦C and were subsequently
stored at−80◦Cuntil processed. BLSA plasma samples were taken
in the morning after an over-night fast and prepared using the
same methodology, and as described previously (Driscoll et al.,
2012). The homeostatic model assessment of insulin resistance
(HOMA-IR) was calculated as follows: insulin (mU/L) × glu-
cose (mg/dL)/405 (Matthews et al., 1985). BMI was calculated as:
body weight (kg)/height (m2) according to previously established
standards (Golden et al., 2010).
PLASMA HORMONE MEASUREMENTS
Insulin, leptin, GIP (Gastric inhibitory peptide), amylin, PYY
(Peptide YY), and PP (Pancreatic polypeptide) were assayed using
a human gut hormone multiplex kit according to the man-
ufacturer’s instructions (Millipore, Billerica, MA). Intra-assay
variation was lower than 11%. Adiponectin levels were mea-
sured by radioimmunoassay (Millipore, Billerica, MA) and the
intra-assay variation for this was from 6.90 to 9.25%. Total
plasma ghrelin levels were measured using an ELISA assay kit
from Millipore according to the manufacturer’s instructions.
Glucagon levels were assayed using a Millipore RIA kit. Brain-
derived neurotrophic factor (BDNF), GH, Agouti-related protein
(AgRP), and prolactin were measured with a Human Brain-
Derived/Pituitary Protein Multiplex Panel assay kit according
to the manufacturer’s instructions (Millipore): intra-assay vari-
ation was lower than 10%. Cytokines were assayed using a
human cytokine/chemokine assay kit according to the manufac-
turer’s instructions (Millipore): intra-assay variation was lower
than 10.5%. C-reactive protein (CRP) was measured using an
ALPCO ELISA kit according to the manufacturer’s instructions
(ALPCO Diagnostics, Salem NH), and the intra-assay variation
was 5.5–6.0%.
Table 1 | Subject characteristics.
Subjects Age Gender (number of male/female) Body mass index Number of CAG repeats
Familial control 48.2±1.9 8/8 26.2±1.4 20.6±0.14
BLSA pre-manifest control 46±2.0 10/5 26.5±1.0 −
BLSA manifest control 57±3.7 5/3 25.4±1.2 −
Pre-manifest subjects 46.8±2.1 10/5 27.4±1.5 42.3±0.09
Manifest subjects 57.6±4.1* 5/3 24.9±1.4 42.5±0.12
*p ≤ 0.01, Significant difference was observed when compared with the familial control group.
Values are mean ± s.e.m. for age, body mass index, and number of CAG repeats.
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GLUCOSE AND LIPID MEASUREMENTS
Plasma glucose levels were measured using a glucose assay kit
(Cayman Chemical Company, Ann Arbor, MI). CH, HDL-C,
LDL-C, triacylglycerols, and free fatty acid levels were mea-
sured using enzymatic assay kits according to the manufacturer’s
instructions (Wako Pure Chemical Industries, Ltd. Japan).
STATISTICAL ANALYSES
One-Way ANOVA was used for the statistical analysis, and
Bonferroni’s multiple-comparison test was used for specific com-
parisons within the five groups using the R software package.
Probability (p) values of < 0.05 were considered statistically
significant for one-to-one comparisons. We further performed
linear regression analysis of hormones levels of individual subjects
by age or BMI, respectively. Standard linear regression analyses
were performed using GraphPad Prism v5.0. Probability (p) val-
ues < 0.05 were considered to have a slope statistically different
from zero.
RESULTS
ALTERED GROWTH FACTORS IN HD SUBJECT PLASMA
As HD pathophysiology is tightly linked to neurodegenera-
tive processes, and potentially peripheral metabolic dysfunction,
we assessed the circulating levels of multiple factors associ-
ated with both of these functions (Figure 1). No difference in
BDNF levels was observed among all five groups (Figure 1A).
Compared to the BLSA control group (396.97 ± 84.67 pg/mL),
manifest HD subjects showed significantly decreased levels
(57.94 ± 14.28 pg/mL) of circulating GH (Figure 1B, p = 0.001).
A similar, non-significant, trend for manifest HD reduced GH
(57.94 ± 14. 28 pg/mL), was also observed compared to the
familial control group (419.98 ± 169.96 pg/mL, p = 0.08). No
difference was observed in the pre-manifest group. Compared
to the BLSA control group (21.48 ± 1.18 pg/mL), pre-manifest
HD subjects showed a significant increase in circulating AgRP
(33.28 ± 3.05 pg/mL, p = 0.007) (Figure 1C), and the same
trend was also observed when compared to the familial controls
(25.14 ± 1.60 pg/mL, p = 0.056). This distinction for AgRP was
not repeated in the manifest HD subjects. Between the two HD
groups, we also observed that there was a reduction in manifest
HD AgRP levels when compared with the pre-manifest HD. With
respect to PRL levels we found a consistent effect, i.e., reduced
PRL levels, in both pre-manifest and manifest HD subjects when
compared to the respective BLSA control groups (Figure 1D).
However, this effect was not observed when compared with the
familial control group.
FIGURE 1 | Growth hormone changes in HD subjects. Plasma BDNF,
growth hormone (GH), Agouti-related protein (AgRP), and prolactin (PRL)
were measured using the Millipore brain-derived protein panel. Data are
mean ± s.e.m., n = 8–16. Statistical analysis was performed using
One-Way ANOVA followed by Bonferroni’s multiple-comparison test,
p ≤ 0.05 (∗, †, ‡, §) and p ≤ 0.01 (∗∗, ††, ‡‡, §§) were considered
statistically significant. ∗ Represents significant difference against familial
control; † represents significant difference against BLSA pre-manifest
control; ‡ represents significant difference against BLSA manifest control
and § represent significant difference against pre-manifest HD subjects.
No change was found in BDNF levels (A). Reduction in GH was
observed in manifest HD subjects (B). Elevation of AgRP was found in
pre-manifest group (C). Reduction of PRL was observed in both pre- and
manifest subjects (D).
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METABOLIC HORMONE CHANGES IN HD SUBJECT PLASMA
To further investigate the potential metabolic aspects of HD
in pre-manifest and manifest subjects, we measured the cir-
culating concentrations of a series of energy-related hormones
including amylin, leptin, ghrelin, adiponectin, glucagon, GIP,
insulin, PYY, and PP in fasted-state plasma (Figure 2). Amylin
levels were found to be significantly elevated in both pre-
manifest and manifest HD subjects (Figure 2A). Leptin levels
were not different in pre-manifest HD subjects, however in
the manifest subjects there was a trend for decreased leptin
levels (Figure 2B, p = 0.13 for familial controls and p = 0.06
for BLSA controls). Compared with the BLSA control group
(298.52 ± 38.26 pg/mL), a significant increase in ghrelin lev-
els in pre-manifest HD subjects (554.26 ± 79.48 pg/mL) was
observed (Figure 2C, p = 0.009). Adiponectin levels were com-
parable among all five groups (Figure 2D). We observed, only
in the manifest HD subjects (39.21 ± 4.03 pg/mL) compared
to the BLSA control (56.02 ± 5.75 pg/mL), a significant reduc-
tion in circulating glucagon levels (Figure 2E, p = 0.045). GIP,
insulin, PYY, and PP levels were not different among all five
groups (Figures 2F–I). In addition, we assessed fasting glucose
levels: as with insulin levels, we found no difference between any
groups.
We also performed linear regression analysis using hormones
and factors against age and BMI. With respect to HD-associated
significant alterations in these regression relationships we found
that leptin- and adiponectin-BMI interactions were affected.
Leptin levels positively correlated with BMI in all three con-
trol groups (Figures S1A–C). Whereas in both pre-manifest HD
and manifest HD subjects, no such correlation was observed
(Figures S1D,E). Furthermore, we found in all control groups
that the adiponectin levels were negatively correlated with BMI
(Figures S2A–C), while in pre-manifest HD and manifest HD
groups, no correlation was found (Figures S2D,E).
FIGURE 2 | Metabolic hormone levels in HD subjects. Plasma levels of
amylin, leptin, ghrelin, adiponectin, glucagon, Gastric inhibitory peptide (GIP),
insulin, peptide YY (PYY), and pancreatic polypeptide (PP) were measured.
Data are means ± s.e.m., n = 8–16. Statistical analysis was performed using
One-Way ANOVA followed by Bonferroni’s multiple-comparison test, p ≤ 0.05
(∗, †, ‡, §) and p ≤ 0.01 (∗∗, ††, ‡‡, §§) were considered statistically significant.
∗ Represents significant difference against familial control; † represents
significant difference against BLSA pre-manifest control; ‡ represents
significant difference against BLSA manifest control and § represent
significant difference against pre-manifest HD subjects. Amylin levels
increased in both pre- and manifest subjects (A). HD manifest subjects have
a trend of reduced leptin levels (B). Both pre- and manifest subjects have
increased ghrelin (C) with a significant difference in the pre-manifest group.
No significant changes were observed for adiponectin (D). Glucagon was
significantly reduced in the manifest subjects (E). No significant differences
were found in the levels of GIP (F), insulin (G), PYY (H), and PP (I).
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PLASMA LIPID PROFILE IN PRE-MANIFEST AND MANIFEST HD
SUBJECTS
We next assessed the circulating lipid profiles of HD subjects to
investigate how their metabolic statusmay affect lipidmetabolism
(Figure 3). Both pre-manifest and manifest HD subjects demon-
strated significantly decreased CH levels compared to the BLSA
control groups (Figure 3A). This significance was also seen in
the manifest HD group when compared with the familial con-
trols. With respect to the HDL-C (Figure 3B), the levels among
the HD and familial control groups were comparable. Whereas
decreased levels were observed in the pre- and manifest HD
groups, compared with their BLSA control groups, LDL-C levels
of pre-manifest HD were decreased relative to the BLSA pre-
manifest controls. LDL-C levels of manifest HD subjects were
less than both familial and BLSA control groups (Figure 3C). No
differences in the LDL-C/HDL-C ratios were observed for pre-
manifest or manifest HD subjects (Figure 3D). No differences in
triacylglycerols (Figure 3E) or free fatty acids levels (Figure 3F)
were observed.
CIRCULATING INFLAMMATORY FACTORS IN HD SUBJECTS
We have previously demonstrated a strong association between
neurodegeneration, metabolic dysfunction, and circulating
inflammatory factors (Johnson et al., 2007; Chadwick et al.,
2008; Stranahan et al., 2012), therefore we assessed circulating
inflammatory mediators including tumor necrosis factor alpha
(TNF-α), CRP as well as interleukins 1, 6, and 10 (IL-1, IL-6,
IL-10) in pre-manifest and manifest HD subjects. As shown in
Figure 4, we found no differences in circulating TNF-α between
any of the experimental groups (Figure 4A). With respect to
CRP levels we found a significant elevation in CRP levels in
pre-manifest HD subjects compared to the BLSA pre-manifest
control group (Figure 4B). A similar trend was also observed
when compared with the familial controls. However, this eleva-
tion was not evident in the manifest HD group. Circulating levels
of the interleukins IL-6, IL-1α, IL-1β, and IL-10 were mostly
below 2–3 pg/mL, such low and minimally-detectable levels
are typical of human subjects that are not presenting excessive
immune responses (Yamamura et al., 1998; Licastro et al., 2000).
HD SUBJECT PLASMA SIGNATURE
Based on the profiles we derived of plasma hormones,
cytokines and lipids, we have generated a preliminary HD
subject plasma signature, i.e., a series of factors the expres-
sion of which is indicative of the pre-manifest and manifest
states in HD (Figure 5). Factors that were uniquely changed
FIGURE 3 | HD subject plasma lipid profiles. Lipids were measured
using enzymatic methods. Data are means ± s.e.m., n = 8–16. Statistical
analysis was performed using One-Way ANOVA followed by Bonferroni’s
multiple-comparison test, p ≤ 0.05 (∗, †, ‡, §) and p ≤ 0.01 (∗∗, ††, ‡‡,
§§) were considered statistically significant. ∗ Represents significant
difference against familial control; † represents significant difference
against BLSA pre-manifest control; ‡ represents significant difference
against BLSA manifest control and § represent significant difference
against pre-manifest HD subjects. Both pre- and manifest HD subjects
have reduced cholesterol, HDL and LDL levels (A–C) while no difference
was found in the ratio of LDL/HDL (D), nor the levels of triacylglycerols
(E) and free fatty acids (F).
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FIGURE 4 | Plasma levels of TNF-α and C-reactive protein in HD. Plasma
levels of TNF-α and C-reactive protein (CRP) were measured. Data are means
± s.e.m., n = 8–16. Statistical analysis was performed using One-Way
ANOVA followed by Bonferroni’s multiple-comparison test, p ≤ 0.05 (∗, †, ‡, §)
and p ≤ 0.01 (∗∗, ††, ‡‡, §§) were considered statistically significant.
∗ Represents significant difference against familial control; † represents
significant difference against BLSA pre-manifest control;
‡ represents significant difference against BLSA manifest control; and
§ represent significant difference against pre-manifest HD subjects. No
difference was observed in the levels of TNF-α. There was a non-significant
trend for increase in TNF-α in the manifest HD group. CRP was increased in
the pre-manifest HD subject plasma compared to BLSA pre-manifest controls.
FIGURE 5 | HD plasma signature. Hormones and cytokines that are
uniquely up- (red) or down-regulated (green) in pre-manifest (black circle) or
manifest subjects (blue circle) as well as those that are commonly up- or
down-regulated in both pre- and manifest HD groups are shown in the Venn
diagram. Amylin is the only factor that was commonly up-regulated in both
pre- and manifest HD group. Prolactin (PRL), total cholesterol (CH), HDL-C,
and LDL-C were commonly down-regulated in both HD groups. Factors that
were uniquely up-regulated in the pre-manifest HD group were AgRP,
ghrelin, and C-reactive protein (CRP). Factors that were uniquely
down-regulated in the manifest HD group were growth hormone (GH) and
glucagon.
(up-regulated) in pre-manifest group were AgRP, ghrelin, and
CRP while in the manifest HD group factors that were
uniquely changed (down-regulated) were GH and glucagon.
Factors that were commonly changed in both pre- and manifest
groups were amylin, prolactin, CH, HDL-C, and LDL-C,
among which amylin is the only factor that was elevated. The
remaining four were decreased in both pre- and manifest HD
groups.
DISCUSSION
In this study we investigated the alterations of circulating
metabolic factors in HD subjects. We found that amylin levels
were significantly increased in both pre-manifest and manifest
HD subjects. GH and Glucagon levels were decreased in the man-
ifest HD subjects compared to BLSA controls. We also found
that levels of AgRP, Ghrelin, and CRP were increased in pre-
manifest HD, PRL levels were reduced in both pre-manifest and
manifest HD cases compared to the BLSA control group. CH as
well as HDL-C and LDL-C were decreased in both HD subject
groups. Pre-manifest HD subjects presented increased CRP levels.
The correlation between leptin levels and BMI was diminished in
both pre- and manifest HD groups, and the negative correlation
between adiponectin and BMI was diminished in both pre and
manifest HD groups.
Amylin is co-secreted with insulin from pancreatic islets in
response to food ingestion (Butler et al., 1990; Pittner et al.,
1994). Amylin is anti-orexigenic and suppresses gastric motil-
ity and glucose uptake (Macdonald, 1997; Gedulin et al., 2006;
Potes et al., 2012). It is also known as islet amyloid peptide and
is closely related to the beta-amyloid peptide that is associated
with the cytotoxic and neurodegenerative aspects of Alzheimer’s
disease (Moreno-Gonzalez and Soto, 2011; Burke et al., 2013).
Elevated fasting amylin levels observed in the current study raised
an interesting speculation that in HD subjects (even in the pre-
manifest subjects) abnormal control of gastrointestinal function
may contribute to the metabolic aspect of the pathology in this
disease. Amylin, like other amyloid molecules, often undergoes
conformational changes to form ion channel-like structures that
may destabilize cellular ionic homeostasis and thus induce cel-
lular degeneration (Quist et al., 2005). Elevated amylin levels
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are typically associated with dysglycemia and pancreatic beta-
cell dysfunction in Type 2 diabetes (Koda et al., 1992; Lorenzo
et al., 1994; Ye et al., 2001). It is therefore interesting, and poten-
tially functionally-relevant, to speculate that the regulation of
amylin levels could be a critical molecular connection between
diverse forms of neurodegenerative diseases that also possess a
metabolic deficit (Martin et al., 2008; Cai et al., 2012). With
our identification of amylin as a potential therapeutic target of
the peripheral metabolic dysfunction in HD, it is possible that
pharmacological manipulation of such a factor could represent
an important avenue for future anti-neurodegenerative therapies
(Martin et al., 2005; Chapter et al., 2010). With respect to the
relationship between HD pathology and somatic metabolism it
is interesting to note that both amylin and ghrelin functionally
target the gut (Butler et al., 1990). Our results therefore demon-
strate an interesting phenomenon of a simultaneous increase of
both an appetite stimulator, ghrelin, and an appetite suppressor,
amylin. This suggests that HD patients possess multiple abnor-
malities in the hormone balance for the regulation of food intake
and absorption. It has been demonstrated that in HD patients,
energy expenditure increases with disease duration, but not with
a greater degree of motor or functional impairment (Aziz et al.,
2010a). Taken together these findings suggest that HD pathology
and metabolic dysfunction may be initiated as a nutrient uptake
and energy utilization deficiency, which then result in weight loss
and dysglycemia.
Our observation of the relatively normal fasting glucose and
insulin levels, as well as normal range HOMA-IR values in our
subjects suggests that neither pre- or manifest HD subjects have
impaired glucose tolerance or insulin resistance. Previous stud-
ies reported that there was no difference in glucose tolerance or
insulin released during oral glucose tolerance test (OGTT) in
early or middle stage HD patients (Kremer et al., 1989; Boesgaard
et al., 2009). However, other studies, including those employ-
ing OGTTs, have demonstrated correlations between abnormal
glycemic control and HD pathophysiology in patients (Podolsky
et al., 1972; Podolsky and Leopold, 1977). These studies together
with our findings suggest that the etiology of HD may be associ-
ated more with general impairment of hormone release and that
glucose regulatory issues caused by this disruption might exist as
an indirect effect.
Glucagon levels were decreased in the manifest HD subjects
compared with BLSA manifest controls and the same trend was
seen when compared with the familial controls. Our finding of
reductions in plasma glucagon level is in accordance with pre-
vious studies in R6/2 transgenic mice (Hurlbert et al., 1999).
In addition to its crucial role in maintaining effective energy
metabolism glucagon can also act as a neuroprotective agent
by reducing the neurotoxic glutamate (Fanne et al., 2011a,b),
therefore reduction of this metabolic regulator may suggest an
important role in mediating HD pathogenesis.
Leptin levels in plasma are usually acutely regulated by fasting
and refeeding, and are also highly correlated to body fat mass in
humans (Maffei et al., 1995; Kolaczynski et al., 1996). In our study
we found a trend for reduced leptin levels in manifest HD sub-
jects. As with the connection between HD pathophysiology and
glycemic control, the specific relationship between leptin and HD
appears highly nuanced. For example, a recent study has demon-
strated that while circulating levels of leptin are similar between
control and HD patients there is an increase in the rate of leptin
secretion of HD patients (Aziz et al., 2010b). Another study has
indicated that leptin levels can be doubled in pre-manifest HD
patients compared to control, albeit in a non-significant man-
ner (Goodman and Barker, 2011). Indicative of the complexity
of energy balance networks, significant reductions in circulat-
ing leptin levels has also been reported (Popovic et al., 2004).
In accordance with previous reports, our linear regression test
showed that in both pre- and manifest HD groups the correlation
between leptin and BMI was lost, also suggesting abnormal leptin
secretion in the HD subjects. It should be noted that with respect
to the disruption of leptin-secretion in HD, the small sample size
and mixed gender may contribute to the degree of variability
observed. With improvement in sample size and gender differ-
ence it is likely that some clinical consensus can be achieved to
the important hormonal systems.
Adiponectin is secreted from adipose tissue and reported to be
negatively correlated with body fat mass (Gavrila et al., 2003). We
found that the adiponectin levels in all the three control groups
showed a significant negative correlation with BMI. However, this
correlation was attenuated in both pre- and manifest HD sub-
jects. Adiponectin mediates insulin sensitization in adipose tissue
via support of insulin signaling and kinase pathways (Ballantyne
et al., 2005). Reductions in adiponectin levels have also been asso-
ciated with obesity and insulin resistance (Kadowaki et al., 2006).
In fact, in two HD animal models, reductions in adiponectin lev-
els occur before body weight loss, suggesting that disruptions
in adipocytokine secretion may be intrinsic to HD pathology
(Phan et al., 2009). Together with our findings, the consistent
changes of leptin and adiponectin in HD, suggests abnormal
adipocyte function is linked to the metabolic alterations in HD
pathophysiology.
In addition to the multiple altered appetite-associated hor-
mones, we found that both GH and prolactin levels were
decreased in manifest HD subjects. Not only is the signaling
activity of prolactin associated with nervous system protective
behavior (Torner et al., 2009), prolactin is also linked with
diabetic pathology, metabolic syndrome and inflammatory con-
ditions (Balbach et al., 2013; Chirico et al., 2013). Impaired
prolactin responses have been reported in the HD patients
(Hayden et al., 1977) as a result of abnormal dopaminergic
activity in hypothalamus. Our results suggest that changes of
basal levels of prolactin are detectable early in pre-manifest
HD subjects. GH actions often synergize with those of pro-
lactin as they are both situated in the hypothalamic-pituitary
system that links both central and peripheral control of energy
metabolism and cellular growth. In the periphery both pro-
lactin and GH can interact to affect energy metabolism (Schäffler
et al., 2005) and immune/inflammatory functions (Redelman
et al., 2008). Reduced GH and prolactin levels suggest that the
HD patients may possess a dysfunctional hypothalamic-pituitary
system (Phelps, 1994; Phelps and Hurley, 1999), which poten-
tially affects food intake and energy balance, leading to further
weight loss and energy insufficiency (Gerardo-Gettens et al., 1989;
Auffret et al., 2012).
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We observed significantly decreased levels of cholesterol, HDL-
C and LDL-C in both pre- andmanifest HD subjects. Formanifest
HD subjects, the same reductions in CH and LDL-C were seen
when compared with both familial and BLSA controls, in accor-
dance with previous reports (Markianos et al., 2008). In addition
to impaired cholesterol synthesis in HD patients (Valenza et al.,
2005), cholesterol changes may also be the result of dysfunction
related to food digestion and absorption, which correlates with
our observation of elevated amylin levels. Cholesterol is impor-
tant for adult brain neuron membrane formation, myelination
and synaptic plasticity (Mauch et al., 2001; Hering et al., 2003;
Quan et al., 2003). Studies have also demonstrated that circulat-
ing cholesterol concentration is related to dementia and emotion
changes (Evans et al., 2000; Dietschy and Turley, 2004). Impaired
cholesterol metabolism was also reported in HD patients recently
(Leoni et al., 2011). In their study reduced plasma level of
24S-hydroxycholesterol (24OHC), the brain specific elimination
product of cholesterol, and reduced levels of the cholesterol pre-
cursors lanosterol and lathosterol were observed, suggesting a
critical role of cholesterol in HD pathology (Leoni et al., 2011).
We found that CRP was significantly elevated in the pre-
manifest HD patients (Figure 4B), as has also been reported by
Stoy et al. (2005). A CRP level of this nature is indicative of the
inflammation of coronary vessels and is related to atheroscle-
rotic process (Lagrand et al., 1999). It is also interesting to note
that in a murine HD model the presence of a progressive cardiac
dysfunction associated with impaired myocardial contractility,
reduced left ventricular pressure and a significantly reduced coro-
nary blood flow has been demonstrated (Wood et al., 2012).
Therefore, it is possible that elevated CRP levels in HD could
be strongly associated with potential cardiac and cardiovascular
dysfunction, which may further exacerbate the disorder. As we
have shown that amylin is elevated in HD patients, this may also
cause cardiovascular issues as amylin is linked to the generation of
stenosing deposits or plaques in the thoracic aorta (Westermark
and Westermark, 2011). It is therefore likely that these two fac-
tors, amylin and CRP, could interact to disrupt both metabolic
and cardiovascular function in HD. Therefore, pharmacothera-
peutic targeting of both or either of these circulating hormone
systems in patients could present an important new avenue for
remedial research.
In conclusion, our study indicates that abnormal hormone lev-
els in HD patients may contribute to the progression of energy
imbalance. The hormones altered in HD affect not only food
intake and absorption, potentially causing weight loss and mal-
nutrition, but also impair interactions among metabolic systems,
thereby inducing more global energy deficits that, ultimately,
could adversely impact CNS function. Our study on both pre- and
manifest HD subjects suggests that metabolic dysfunction occurs
before the onset of diagnosable HD symptomology. It is possible
that along with its deleterious actions on central nervous tissue,
aggregated mutant HTT protein may also have direct effects on
peripheral tissues such as the intestine, pancreas and adipose tis-
sue. We have previously demonstrated in animal models of HD
that therapeutic targeting of these peripheral energy-regulating
organs can be beneficial for HD pathologies (Martin et al., 2012).
Therefore, our current study further supports the idea that a
combined therapeutic strategy, targeting both central and periph-
eral systems, may prove effective at ameliorating this devastating
genetic disorder.
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Figure S1 | Correlation between leptin levels and the body mass index
(BMI). Linear regression test was performed using leptin levels against the
BMI. p ≤ 0.05 was considered statistically significant with respect to the
linear correlations’ deviation from a zero slope. r2 correlation was
calculated by GraphPad Prism v5.0. In familial, BLSA pre-manifest, and
manifest control groups, leptin levels were positively correlated with the
BMI (A–C); in pre-manifest HD and manifest HD groups no correlation
was observed (D,E).
Figure S2 | Correlation between adiponectin levels and the body mass
index (BMI). Linear regression test was performed using adiponectin
levels against the BMI. p ≤ 0.05 was considered statistically significant
with respect to the linear correlations’ deviation from a zero slope. r2
correlation was calculated by GraphPad Prism v5.0. In familial, BLSA
pre-manifest, and manifest control groups, adiponectin levels were
negatively correlated with the BMI (A–C); whereas in pre-manifest HD and
manifest HD groups no such correlation was observed (D,E).
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